Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Nemecek

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Blood Advances|April 16, 2024
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocolSarah Nikiforow, Jennifer S Whangbo, Ran Reshef, et al.
Transplantation and Cellular Therapy|August 31, 2022
Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE StudyPaul A Carpenter, Hyoung Jin Kang, Keon Hee Yoo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 9, 2014
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trialLauri M Burroughs, Eneida R Nemecek, Troy R Torgerson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 6, 2010
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignanciesEneida R Nemecek, Katherine A Guthrie, Mohamed L Sorror, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2011
Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remissionEneida R Nemecek, Kristin Ellis, Wensheng He, et al.
Bone Marrow Transplantation|March 28, 2018
Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantationChristine N Duncan, Ruta Brazauskas, Jiaxing Huang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2015
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trialC S Fuchs, S Azevedo, T Okusaka, et al.
Haematologica|June 30, 2018
A phase II/III randomized, multicenter trial of prednisone/sirolimus <i>versus</i> prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-<i>versus</i>-host disease: BMT CTN 0801Paul A Carpenter, Brent R Logan, Stephanie J Lee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2015
Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic LeukemiaParinda A Mehta, Mei-Jie Zhang, Mary Eapen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2021
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic MalignanciesLeo Luznik, Marcelo C Pasquini, Brent Logan, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Blood Advances|April 16, 2024
Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocolSarah Nikiforow, Jennifer S Whangbo, Ran Reshef, et al.
Transplantation and Cellular Therapy|August 31, 2022
Ibrutinib Treatment of Pediatric Chronic Graft-versus-Host Disease: Primary Results from the Phase 1/2 iMAGINE StudyPaul A Carpenter, Hyoung Jin Kang, Keon Hee Yoo, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 9, 2014
Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trialLauri M Burroughs, Eneida R Nemecek, Troy R Torgerson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 6, 2010
Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignanciesEneida R Nemecek, Katherine A Guthrie, Mohamed L Sorror, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 21, 2011
Outcome of myeloablative conditioning and unrelated donor hematopoietic cell transplantation for childhood acute lymphoblastic leukemia in third remissionEneida R Nemecek, Kristin Ellis, Wensheng He, et al.
Bone Marrow Transplantation|March 28, 2018
Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantationChristine N Duncan, Ruta Brazauskas, Jiaxing Huang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2015
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trialC S Fuchs, S Azevedo, T Okusaka, et al.
Haematologica|June 30, 2018
A phase II/III randomized, multicenter trial of prednisone/sirolimus <i>versus</i> prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-<i>versus</i>-host disease: BMT CTN 0801Paul A Carpenter, Brent R Logan, Stephanie J Lee, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 14, 2015
Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic LeukemiaParinda A Mehta, Mei-Jie Zhang, Mary Eapen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2021
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic MalignanciesLeo Luznik, Marcelo C Pasquini, Brent Logan, et al.
Pageof 7